paper
describ
propos
strateg
vaccin
facil
svf
provid
capabl
uk
deal
new
emerg
diseas
threat
would
underpin
vaccin
manufactur
industri
develop
expertis
technolog
enabl
rapid
manufactur
small
batch
vaccin
emerg
use
agent
bioterrorist
agent
emerg
diseas
would
rare
abil
work
danger
pathogen
contain
allow
product
inactiv
live
vaccin
would
difficult
convent
plant
facil
output
includ
vaccin
candid
manufactur
protocol
transfer
industri
small
vaccin
batch
emerg
use
clinic
trial
vaccin
refer
standard
would
also
avail
manufactur
small
batch
experiment
public
health
vaccin
uk
develop
world
allow
clinic
trial
undertaken
key
diseas
crown
threat
infecti
diseas
spread
popul
either
natur
deliber
introduct
requir
govern
plan
strategi
deal
threat
protect
nation
health
includ
plan
manufactur
stockpil
medic
countermeasur
antibiot
vaccin
vaccin
key
defenc
infecti
diseas
industri
manufactur
vaccin
commerci
interest
littl
incent
develop
vaccin
specul
basi
threat
may
materialis
two
parliamentari
committe
uk
identifi
need
manufactur
facil
respond
rapidli
produc
vaccin
infecti
diseas
pose
threat
uk
paper
outlin
propos
meet
need
strateg
vaccin
facil
svf
would
provid
opportun
develop
product
process
varieti
experiment
vaccin
could
test
clinic
trial
pass
onto
industri
product
indic
even
immedi
demand
product
vaccin
new
influenza
strain
could
still
develop
point
allow
rapid
product
industri
time
need
eg
prepar
good
manufactur
practic
gmp
seed
bank
would
provid
strateg
capabl
cope
infecti
diseas
signific
part
uk
prepared
plan
paper
set
concept
strateg
vaccin
facil
enhanc
uk
capabl
deal
new
emerg
diseas
pathogen
capabl
caus
widespread
diseas
emerg
time
inher
unpredict
know
next
seriou
diseas
epidem
aris
natur
epidem
anoth
notori
featur
pathogen
abil
spread
larg
area
rel
littl
time
fuell
increas
intern
travel
diseas
year
ago
would
confin
small
remot
area
rapidli
spread
worldwid
short
time
span
chang
environment
condit
global
warm
clear
forest
agricultur
widespread
dam
arid
region
also
factor
emerg
diseas
number
differ
factor
involv
pathogen
abil
emerg
diseas
threat
main
factor
outlin
tabl
owe
constantli
chang
ecolog
social
factor
imposs
predict
next
emerg
pathogen
import
human
health
pathogen
disappear
nich
well
emerg
malaria
endem
uk
marsh
drainag
wipe
main
local
mosquito
vector
anophel
atroparvu
uk
possibl
mosquito
find
nich
uk
malaria
becom
endem
inde
number
report
airport
malaria
case
uk
peopl
live
near
airport
incom
flight
malaria
endem
zone
infect
without
abroad
transfer
infecti
diseas
human
activ
air
travel
seriou
public
health
risk
case
import
dengu
viru
infect
uk
year
dr
g
lloyd
person
commun
sever
import
case
lassa
fever
european
countri
record
potenti
organ
establish
new
countri
import
especi
vector
mosquito
speci
capabl
transmit
infect
present
west
nile
viru
wnv
epidem
us
began
import
viru
new
york
quickli
establish
local
mosquito
popul
thenc
spread
state
year
rout
import
viru
yet
establish
sar
becam
intern
problem
due
rapid
spread
novel
coronaviru
china
countri
air
travel
infect
passeng
spanish
influenza
pandem
caus
strain
influenza
viru
thought
arisen
due
major
reassort
shift
viru
gene
result
chang
major
surfac
protein
ultim
result
viru
capabl
effici
humantohuman
spread
popul
time
littl
preexist
immun
diseas
spread
across
world
matter
month
kill
million
peopl
two
less
sever
influenza
pandem
also
aros
last
centuri
asian
flu
hong
kong
flu
pandem
caus
strain
thought
arisen
genet
reassort
avian
human
influenza
virus
recent
year
seen
emerg
increas
number
highli
pathogen
avian
influenza
virus
capac
infect
human
none
recent
outbreak
result
widespread
humantohuman
transmiss
emerg
strain
influenza
capabl
may
matter
time
introduct
vaccin
last
two
centuri
herald
era
diseas
control
culmin
erad
smallpox
late
recent
advanc
vaccin
manufactur
increas
understand
immunolog
pathogenhost
interact
expand
repertoir
approach
made
produc
vaccin
individu
diseas
diseas
vaccin
easili
produc
inactiv
pathogen
exampl
influenza
vaccin
vaccin
diseas
may
difficult
produc
vaccin
hiv
still
elud
us
despit
nearli
year
work
mani
research
group
mani
countri
emerg
diseas
would
possibl
produc
vaccin
base
track
record
vaccin
relat
strain
vaccin
programm
may
need
sophist
approach
product
attenu
subunit
genet
modifi
vector
vaccin
sophist
vaccin
develop
gener
requir
major
invest
take
mani
year
complet
much
burden
diseas
occur
develop
countri
diseas
tb
malaria
measl
hiv
parasit
diseas
account
major
morbid
mortal
due
infecti
diseas
mani
case
vaccin
develop
manufactur
overlook
larg
pharmaceut
compani
sinc
high
cost
develop
vaccin
diseas
attract
econom
proposit
vaccin
develop
therefor
reli
research
grant
public
bodi
relief
organis
small
research
group
take
work
necessari
fund
facil
manufactur
vaccin
candid
particularli
qualiti
standard
demand
use
human
clinic
trial
diseas
hiv
malaria
far
evad
effect
vaccin
develop
due
complex
structur
interact
host
mani
research
programm
avail
develop
promis
vaccin
candid
exampl
current
development
program
includ
vaccin
plagu
ebola
botulinum
toxin
candid
could
taken
forward
vaccin
manufactur
emerg
situat
updat
inform
current
vaccin
develop
work
requir
order
draw
quickli
upon
inform
emerg
tabl
give
potenti
vaccin
develop
number
diseas
may
present
risk
popul
either
natur
emerg
deliber
releas
success
vaccin
develop
evalu
requir
access
wide
rang
research
evalu
techniqu
addit
fundament
skill
bacteriolog
virolog
also
includ
wide
rang
molecular
biolog
techniqu
essenti
mani
modern
vaccin
techniqu
genom
programm
contribut
significantli
identifi
potenti
vaccin
candid
new
organ
abil
studi
immun
respons
man
anim
provid
satisfactori
anim
model
also
key
new
vaccin
design
product
evalu
abil
work
within
strictest
mode
biolog
contain
critic
oper
propos
facil
undertak
regular
oper
facil
ensur
oper
remain
fulli
train
requisit
experi
requir
develop
product
emerg
situat
requir
facil
spend
nonemerg
time
work
differ
type
microorgan
use
rang
differ
techniqu
oper
skill
maintain
highest
level
time
order
maintain
practic
skill
base
provid
date
expertis
varieti
techniqu
plant
would
undertak
rang
smallscal
product
program
could
contract
industri
partnership
collabor
academia
public
research
bodi
govern
depart
worldwid
need
new
vaccin
deal
public
health
problem
third
world
svf
would
well
place
contribut
global
health
develop
manufactur
protocol
clinic
trial
batch
materi
candid
vaccin
area
conjunct
intern
aid
commun
facil
design
need
meet
number
vari
requir
satisfi
rang
activ
could
call
upon
hous
includ
necessari
servic
support
gmp
purifi
water
suppli
system
monitor
environ
equip
abil
accommod
differ
product
method
cell
cultur
egg
cultur
virus
ferment
process
vaccin
base
bacteri
express
protein
product
effluent
treatment
plant
suitabl
autoclav
deal
contamin
wast
equip
space
downstream
process
purif
fill
finish
complet
inhous
access
qualiti
control
laboratori
media
prepar
laboratori
equip
prepar
servic
good
order
store
servic
engin
support
abil
support
one
manufactur
process
wide
skill
base
sustain
mainten
facil
schedul
allow
oper
continu
part
whilst
undertaken
product
unit
scale
allow
product
batch
size
suitabl
clinic
trial
includ
phase
exact
number
vaccin
dose
per
batch
would
depend
natur
process
entir
plant
capabl
rapid
clean
turnaround
part
oper
parallel
produc
larger
quantiti
materi
emerg
modular
facil
base
separ
small
product
unit
hous
shell
maintain
gmp
standard
consid
like
candid
facil
design
unit
would
essenti
group
room
servic
equip
brought
need
whenev
possibl
dispos
unit
would
use
ferment
centrifug
vessel
contain
unit
minimis
valid
clean
procedur
necessari
product
run
dispos
facil
also
mean
much
gmp
qualiti
assur
paperwork
duplic
differ
product
care
design
allow
dispos
element
contain
shell
interfac
highcost
compon
air
handl
system
way
allow
rapid
clean
process
improv
turnaround
facil
owe
threat
bioterror
emerg
diseas
propos
strateg
vaccin
facil
uk
mitig
threat
facil
must
abl
work
highest
contain
level
conform
gmp
standard
order
maintain
capabl
base
envisag
facil
would
use
manufactur
smallscal
gmp
batch
vaccin
clinic
trial
nich
market
one
possibl
role
svf
develop
vaccin
key
public
health
diseas
affect
third
world
nation
view
transfer
manufactur
process
vaccin
manufactur
industri
countri
provis
svf
uk
would
enhanc
nation
vaccin
manufactur
capabl
would
place
uk
strong
posit
fight
bioterror
emerg
infect
